Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Qiagen NV receives FDA Approval of artus CMV RGQ MDx Kit


Wednesday, 18 Jun 2014 04:00pm EDT 

Qiagen NV:Says its artus CMV RGQ MDx Kit for human cytomegalovirus (CMV) has been approved by U.S. Food and Drug Administration (FDA) under full premarket approval (PMA).Test is the only FDA-approved PCR-based assay optimized for low- to mid-throughput testing of CMV.With a turn-around time of about three hours, the assay provides faster results than other PMA approved tests.artus CMV RGQ MDx runs on QIAGEN's Rotor-Gene Q MDx real-time PCR platform, which was cleared by the FDA in 2012 and is a member of the QIAsymphony modular family of automated instruments. 

Company Quote

23.61
0.41 +1.77%
26 Dec 2014